Description
Wockhardt Hospitals covers achievements, branding, communication etc.
Market
The economic boom and lifestyle changes are fast fuelling the growth of the Indian pharma and health care sectors. As per indications, the industry is already growing faster than the world average and will in all likelihood double its business in a few years. Pharmaceutical and health care are the two sunrise industries in India. One of the companies that straddles both these segments is Wockhardt. Wockhardt is India’s leading research-based global health care enterprise with relevance in the fields of biotechnology, pharmaceuticals, nutraceuticals and super speciality hospitals. It has grown by leveraging two powerful trends impacting the world of medicine – globalisation and innovation. With five research centres and fifteen manufacturing plants dotting various countries and continents across the globe, Wockhardt’s multi-cultural, multi-ethnic workforce of 10,000 from fourteen nationalities work in businesses ranging from the manufacture and marketing of
pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs), vaccines, medical nutrition and animal health products. The company also demonstrates a robust, multi-disciplinary R&D programme with more than 500 scientists – including 100 who hold PhD degrees – covering biotechnology, pharmaceutical chemistry and new drug discovery, as well as novel drug delivery systems (NDDS). The Group’s flagship company, Wockhardt Limited, had a turnover of US$ 673 million (Rs. 2650 crore) in 2007 (Source: Wockhardt Limited Annual Report) and is on schedule to cross US$ 1 billion in 2009.
Achievements
The achievements of this dynamic company are long and distinguished. It has converted acquisitions into a fine art, quickly absorbing the strengths of the company and ensuring its unrestricted growth. Wockhardt’s European acquisitions include Wallis and CP Pharmaceuticals in the UK, esparma in Germany, Pinewood in Ireland and Negma Laboratories in France. With these strategic acquisitions, Wockhardt has become the largest Indian pharmaceutical company in the European continent, contributing more than 54% to Wockhardt’s annual revenues. Most recently, Wockhardt acquired Morton Grove Pharmaceuticals Inc. in the US. The company’s focus on research is a key aspect of its future growth. Wockhardt
pioneered medical biotechnology in India and recognised its role in developing a new stream of drugs and delivery mechanisms. Wockhardt is the first company to receive BIO-IND for recombinant insulin injectibles, for initiating clinical trials in the US. At the same time, Wockhardt received a major impetus when the Drug Controller General of India (DCGI) approved the marketing of insulin analogue – Glargine – a long-acting insulin in India. After the originator, Wockhardt is the second company to have developed this technologydriven insulin analogue. Wockhardt has a robust R&D and clinical research programme in place. In 2007, it filed 25 abbreviated new drug applications (ANDA) in the US and seven marketing authorisations (MA) in Europe. In addition, Wockhardt has also filed 204 patents. Wockhardt’s new drug discovery programme is moving firmly ahead with anti-infective molecules WCK-771 completing Phase-II clinical trials and the oral pro-drug WCK-2349 obtaining the Drug Controllers’ assent for Phase-I trials. These apart, the company also has three new lead molecules that it has pressed into the pre-clinical trial stage. The Group’s hospital arm, Wockhardt Hospitals, also has a distinguished presence in India. Comprising a chain of fifteen super speciality hospitals spread across the length and breadth of the country, Wockhardt Hospitals is an associate hospital of Harvard Medical International, the international arm of Harvard Medical School in Boston, US. Wockhardt Hospitals has a strong focus on critical health care areas such as cardiology and cardiac surgery, orthopaedics, neurology and neuro surgery, urology and nephrology. To its credit are several advanced procedures including Awake Heart Surgery and Minimally Invasive Brain and
Spine surgeries that have constantly brought them in the news for their path-breaking innovative procedures. At the Asian Hospital Management Awards 2007 in Thailand, Wockhardt Hospitals was adjudged the winner from amongst 282 contender projects from 75 hospitals in 17 countries for the most outstanding project in Patient Safety/Quality Medical Care category. The Hospital Management Asia awards are presented in association with international
authorities such as Joint Commission International, John Hopkins Medicine International, American Hospital Management Company, IBM, International Hospital Federation and World Health Organisation. These accolades have achieved two things: they have strengthened the hospitals’ resolve to make a telling difference to health care in India; at the same time they have underscored the fact that the hospitals’ advanced medical procedures are manned by a formidable clinical talent. If further ratification was required then Wockhardt’s super speciality hospital in Mumbai became one of the first hospitals in South Asia to receive accreditation from the Joint Commission International (JCI).
companies in the country and the second largest hospital generics supplier. It successfully launched nicotine replacement therapy (NRT) patches and lozenges. Today, oncology is fast emerging as a promising business segment across the globe. This forms a fundamental area of focus for Wockhardt UK. From amongst its recent acquisitions, Pinewood Laboratories has seven of its ten products ranked number one while the remaining three occupy the second slot. The company is a leader in the renal business in Ireland. After the Morton Grove acquisition tabloid – Wockhardt Medical Times – that is distributed amongst the medical fraternity elucidating recent medical trends and procedures carried out globally.
History
Habil Khorakiwala, Chairman Wockhardt Limited, launched the company nearly four decades ago. He inculcated and nurtured management processes that typified an open culture, participative practices, continuous innovation, speedy response and customer focus. Wockhardt is amongst the top five health care groups in India and has built a strong presence in the health care business encompassing pharmaceutical formulations, API’s, biopharmaceuticals, vaccines and infant nutrition, with a unique business model that spans the entire chain from concept to marketing. The company went public in 1992; the following sixteen years narrate Wockhardt's story of dramatic transformation from a local firm to a global player. Wockhardt was amongst the first pharmaceutical companies in India to see the forces of globalisation sweeping the world and began to look at acquisitions as a major growth avenue. Today, after a string of acquisitions, mergers and strategic alliances, Wockhardt can truly be called an Indian multi-national company.
Brand Values
Inspired by determination and the ability to seize every moment, every opportunity, brand Wockhardt is one of India’s most respected companies globally. Wockhardt’s brand value is best encapsulated in its corporate vision – To be the most admired health care group from India. Wockhardt’s transformation from a domestic firm to an organisation with a global footprint is a fascinating chronicle of innovation, enterprise, entrepreneurship and knowledge management. From inception the company has provided the medical community with high-quality, innovative drugs and has taken pride at the contribution it has made to medical health care in India.
Wockhardt now has 58 products in the US market – possibly the largest portfolio of any Indian pharmaceutical company.
www.wockhardt.com www.wockhardthospitals.net
THINGS YOU DIDN’T KNOW ABOUT
Recent Developments
The acquisitions have significantly expanded and strengthened Wockhardt’s presence in Europe and the US. But acquisitions are not just about negotiations and taking over entire organisations. Back in India, Wockhardt is charged with the task of seamlessly integrating them into a new milieu and a new culture. Using technology as a catalyst, all locations are being linked in real-time on the SAP radar. Thanks to the energy that has been generated, Wockhardt has pressed into motion a number of strategies for a bigger global footprint and created the ground for an increased market presence. It has acquired for all its fifteen manufacturing facilities either a USFDA or an MHRA approval and certification. These plants have the requisite capacity to manufacture all dosage forms and are already playing a significant role in contract manufacturing.
Wockhardt
Wockhardt is the largest Indian pharmaceutical company in Europe Wockhardt’s international business contributes 71% to the company’s annual revenues Negma’s osteoarthritis brand, ART50 is one of the world’s foremost anti-rheumatic drug Morton Grove Pharmaceuticals is a leading liquid generic and speciality dermatology company with a complete range of dosage forms from tablets and capsules to liquids and injectibles Wockhardt has in-licensing arrangements with companies from the US and Europe for drugs in the fast-growing areas of dermatology, derma-cosmetology, nutraceuticals and osteoarthritis In 2007, eight of Wockhardt’s brands featured in India’s Top 300 Pharma Brands and two – Spasmo-Proxyvon and Dexolac – in the Top 100 Wockhardt is only the second company in the world – after the originator – to have developed Glargine, a technology-driven insulin analogue Wockhardt has received 45 regulatory approvals for recombinant insulin – Wosulin – in the rest-of-the-world markets Wockhardt Hospitals is a global leader in conscious off-pump coronary bypass surgery – a modern medical procedure where the patient is fully awake and alert during the operation Wockhardt is poised to become a US$1 billion pharmaceutical company by 2009
Product
With its global operations in biotechnology and pharmaceuticals, Wockhardt has a large product portfolio in different therapeutic segments. There are over 1200 products in fields such as diabetology, pain-management, neurology, nephrology, infection, respiratory, dermatology, derma-cosmetology, oncology, nutrition and osteoarthritis, amongst others. Wockhardt is the first Indian company in the European continent with a balanced portfolio comprising patented and generic products. Wockhardt UK is one of the top ten generics
Promotion
Wockhardt’s pharmaceutical products are promoted ethically to more than 175,000 doctors in India. Well-educated and highly trained Territory Managers interact with both doctors and pharmacists on Wockhardt’s products. The company conducts continuous medical education (CME) programmes on product-related medical topics, providing doctors with updates on diseases and the latest available therapeutic options. Wockhardt also publishes a monthly
doc_652988564.pdf
Wockhardt Hospitals covers achievements, branding, communication etc.
Market
The economic boom and lifestyle changes are fast fuelling the growth of the Indian pharma and health care sectors. As per indications, the industry is already growing faster than the world average and will in all likelihood double its business in a few years. Pharmaceutical and health care are the two sunrise industries in India. One of the companies that straddles both these segments is Wockhardt. Wockhardt is India’s leading research-based global health care enterprise with relevance in the fields of biotechnology, pharmaceuticals, nutraceuticals and super speciality hospitals. It has grown by leveraging two powerful trends impacting the world of medicine – globalisation and innovation. With five research centres and fifteen manufacturing plants dotting various countries and continents across the globe, Wockhardt’s multi-cultural, multi-ethnic workforce of 10,000 from fourteen nationalities work in businesses ranging from the manufacture and marketing of
pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs), vaccines, medical nutrition and animal health products. The company also demonstrates a robust, multi-disciplinary R&D programme with more than 500 scientists – including 100 who hold PhD degrees – covering biotechnology, pharmaceutical chemistry and new drug discovery, as well as novel drug delivery systems (NDDS). The Group’s flagship company, Wockhardt Limited, had a turnover of US$ 673 million (Rs. 2650 crore) in 2007 (Source: Wockhardt Limited Annual Report) and is on schedule to cross US$ 1 billion in 2009.
Achievements
The achievements of this dynamic company are long and distinguished. It has converted acquisitions into a fine art, quickly absorbing the strengths of the company and ensuring its unrestricted growth. Wockhardt’s European acquisitions include Wallis and CP Pharmaceuticals in the UK, esparma in Germany, Pinewood in Ireland and Negma Laboratories in France. With these strategic acquisitions, Wockhardt has become the largest Indian pharmaceutical company in the European continent, contributing more than 54% to Wockhardt’s annual revenues. Most recently, Wockhardt acquired Morton Grove Pharmaceuticals Inc. in the US. The company’s focus on research is a key aspect of its future growth. Wockhardt
pioneered medical biotechnology in India and recognised its role in developing a new stream of drugs and delivery mechanisms. Wockhardt is the first company to receive BIO-IND for recombinant insulin injectibles, for initiating clinical trials in the US. At the same time, Wockhardt received a major impetus when the Drug Controller General of India (DCGI) approved the marketing of insulin analogue – Glargine – a long-acting insulin in India. After the originator, Wockhardt is the second company to have developed this technologydriven insulin analogue. Wockhardt has a robust R&D and clinical research programme in place. In 2007, it filed 25 abbreviated new drug applications (ANDA) in the US and seven marketing authorisations (MA) in Europe. In addition, Wockhardt has also filed 204 patents. Wockhardt’s new drug discovery programme is moving firmly ahead with anti-infective molecules WCK-771 completing Phase-II clinical trials and the oral pro-drug WCK-2349 obtaining the Drug Controllers’ assent for Phase-I trials. These apart, the company also has three new lead molecules that it has pressed into the pre-clinical trial stage. The Group’s hospital arm, Wockhardt Hospitals, also has a distinguished presence in India. Comprising a chain of fifteen super speciality hospitals spread across the length and breadth of the country, Wockhardt Hospitals is an associate hospital of Harvard Medical International, the international arm of Harvard Medical School in Boston, US. Wockhardt Hospitals has a strong focus on critical health care areas such as cardiology and cardiac surgery, orthopaedics, neurology and neuro surgery, urology and nephrology. To its credit are several advanced procedures including Awake Heart Surgery and Minimally Invasive Brain and
Spine surgeries that have constantly brought them in the news for their path-breaking innovative procedures. At the Asian Hospital Management Awards 2007 in Thailand, Wockhardt Hospitals was adjudged the winner from amongst 282 contender projects from 75 hospitals in 17 countries for the most outstanding project in Patient Safety/Quality Medical Care category. The Hospital Management Asia awards are presented in association with international
authorities such as Joint Commission International, John Hopkins Medicine International, American Hospital Management Company, IBM, International Hospital Federation and World Health Organisation. These accolades have achieved two things: they have strengthened the hospitals’ resolve to make a telling difference to health care in India; at the same time they have underscored the fact that the hospitals’ advanced medical procedures are manned by a formidable clinical talent. If further ratification was required then Wockhardt’s super speciality hospital in Mumbai became one of the first hospitals in South Asia to receive accreditation from the Joint Commission International (JCI).
companies in the country and the second largest hospital generics supplier. It successfully launched nicotine replacement therapy (NRT) patches and lozenges. Today, oncology is fast emerging as a promising business segment across the globe. This forms a fundamental area of focus for Wockhardt UK. From amongst its recent acquisitions, Pinewood Laboratories has seven of its ten products ranked number one while the remaining three occupy the second slot. The company is a leader in the renal business in Ireland. After the Morton Grove acquisition tabloid – Wockhardt Medical Times – that is distributed amongst the medical fraternity elucidating recent medical trends and procedures carried out globally.
History
Habil Khorakiwala, Chairman Wockhardt Limited, launched the company nearly four decades ago. He inculcated and nurtured management processes that typified an open culture, participative practices, continuous innovation, speedy response and customer focus. Wockhardt is amongst the top five health care groups in India and has built a strong presence in the health care business encompassing pharmaceutical formulations, API’s, biopharmaceuticals, vaccines and infant nutrition, with a unique business model that spans the entire chain from concept to marketing. The company went public in 1992; the following sixteen years narrate Wockhardt's story of dramatic transformation from a local firm to a global player. Wockhardt was amongst the first pharmaceutical companies in India to see the forces of globalisation sweeping the world and began to look at acquisitions as a major growth avenue. Today, after a string of acquisitions, mergers and strategic alliances, Wockhardt can truly be called an Indian multi-national company.
Brand Values
Inspired by determination and the ability to seize every moment, every opportunity, brand Wockhardt is one of India’s most respected companies globally. Wockhardt’s brand value is best encapsulated in its corporate vision – To be the most admired health care group from India. Wockhardt’s transformation from a domestic firm to an organisation with a global footprint is a fascinating chronicle of innovation, enterprise, entrepreneurship and knowledge management. From inception the company has provided the medical community with high-quality, innovative drugs and has taken pride at the contribution it has made to medical health care in India.
Wockhardt now has 58 products in the US market – possibly the largest portfolio of any Indian pharmaceutical company.
www.wockhardt.com www.wockhardthospitals.net
THINGS YOU DIDN’T KNOW ABOUT
Recent Developments
The acquisitions have significantly expanded and strengthened Wockhardt’s presence in Europe and the US. But acquisitions are not just about negotiations and taking over entire organisations. Back in India, Wockhardt is charged with the task of seamlessly integrating them into a new milieu and a new culture. Using technology as a catalyst, all locations are being linked in real-time on the SAP radar. Thanks to the energy that has been generated, Wockhardt has pressed into motion a number of strategies for a bigger global footprint and created the ground for an increased market presence. It has acquired for all its fifteen manufacturing facilities either a USFDA or an MHRA approval and certification. These plants have the requisite capacity to manufacture all dosage forms and are already playing a significant role in contract manufacturing.
Wockhardt
Wockhardt is the largest Indian pharmaceutical company in Europe Wockhardt’s international business contributes 71% to the company’s annual revenues Negma’s osteoarthritis brand, ART50 is one of the world’s foremost anti-rheumatic drug Morton Grove Pharmaceuticals is a leading liquid generic and speciality dermatology company with a complete range of dosage forms from tablets and capsules to liquids and injectibles Wockhardt has in-licensing arrangements with companies from the US and Europe for drugs in the fast-growing areas of dermatology, derma-cosmetology, nutraceuticals and osteoarthritis In 2007, eight of Wockhardt’s brands featured in India’s Top 300 Pharma Brands and two – Spasmo-Proxyvon and Dexolac – in the Top 100 Wockhardt is only the second company in the world – after the originator – to have developed Glargine, a technology-driven insulin analogue Wockhardt has received 45 regulatory approvals for recombinant insulin – Wosulin – in the rest-of-the-world markets Wockhardt Hospitals is a global leader in conscious off-pump coronary bypass surgery – a modern medical procedure where the patient is fully awake and alert during the operation Wockhardt is poised to become a US$1 billion pharmaceutical company by 2009
Product
With its global operations in biotechnology and pharmaceuticals, Wockhardt has a large product portfolio in different therapeutic segments. There are over 1200 products in fields such as diabetology, pain-management, neurology, nephrology, infection, respiratory, dermatology, derma-cosmetology, oncology, nutrition and osteoarthritis, amongst others. Wockhardt is the first Indian company in the European continent with a balanced portfolio comprising patented and generic products. Wockhardt UK is one of the top ten generics
Promotion
Wockhardt’s pharmaceutical products are promoted ethically to more than 175,000 doctors in India. Well-educated and highly trained Territory Managers interact with both doctors and pharmacists on Wockhardt’s products. The company conducts continuous medical education (CME) programmes on product-related medical topics, providing doctors with updates on diseases and the latest available therapeutic options. Wockhardt also publishes a monthly
doc_652988564.pdf